Intuitive Surgical (NASDAQ: ISRG) has seen its stock drop over 17% this year despite being the leading manufacturer of robotic surgical systems, particularly with its da Vinci Xi platform, which was utilized in over 3 million procedures last year. The emergence of competitors like Johnson & Johnson and Medtronic, along with FDA-approved alternatives from Restore Robotics, raises concerns about Intuitive’s market dominance. However, the entrenched position of da Vinci systems in hospitals, supported by surgeon training and established workflows, creates significant barriers for competitors.
The company’s financial performance remains robust, with 2025 revenues reaching $10.1 billion and a gross profit margin projected between 67% and 68% for 2026. The rollout of the da Vinci 5, featuring advanced technology aimed at improving surgical outcomes, is expected to drive further growth. Intuitive’s strong installed base and recurring revenue model position it well for sustained success despite increased competition.
For market professionals, Intuitive Surgical represents a compelling long-term investment opportunity, driven by surgeon loyalty, a significant existing footprint, and continuous innovation in robotic surgery technology.
Source: fool.com